The global CRO where clinical trials run on time

Finding a CRO to deliver your pivotal Phase 2 & 3 clinical trials on time and on budget isn’t easy. Choose the CRO you can trust.

Therapeutic areas

Inflammatory Bowel Diseases (IBD)

Crohns’ Disease, Ulcerative Colitis and other IBDs.

Oncology

Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Ovarian Cancer, Radiopharmaceuticals and other Oncology indications.

Hematology

Multiple Myeloma, Lymphomas, Leukemias and other oncohematological indications.

Infectious Diseases

Antimicrobial and Antifungal infections and other ID.

Multiple Sclerosis

Multiple Sclerosis, Spasticity and other neurological indications.

Rare Diseases

Hemophilia A & B, Von Willebrand Disease, Thrombocytopenia, Polycythemia Vera, Paroxysmal Nocturnal Hemoglobinuria (PNH).

Asset 41

Get Control Over
Clinical Trial Planning

Get to know our proprietary technology platform used for clinical trial planning, budgeting and tracking of clinical trial finances.

PSI On Point

The PSI Advantage

PSI CRO has received 2024 CRO Leadership Awards in the categories of Expertise, Quality, Compatibility, and Reliability in the Overall (combined Big and Small Pharma) respondent group. This is the seventh consecutive year that PSI has received leadership awards presented by Clinical Leader and Life Science Connect based on research conducted by ISR. The awards recognize CROs that are voted by sponsors to meet or exceed expectations.

PSI wins CRO Leadership Awards for Expertise, Compatibility, Quality, and Reliability

Your last patient in is our first priority

PSI has been exceedingly professional and is respected by our site as a great collaborator.

Anthony W. Tolcher, MD, FRCP, FACP